 |
Microneedle Flu Vaccine Market |
Micro-needles are a novel type of dosage delivery method that can easily overcome the issues that occur with traditional formulations.
The Microneedle Flu Vaccine Market is made up of micron-sized needles that are organized on a tiny dermal patch.
The primary premise of micro-needles is to rupture the skin layer, resulting in a micron-sized drug delivery channel in which medications can easily be delivered from the epidermis or upper dermis region to the systemic circulation without encountering any barriers.
Microneedle Flu Vaccine Market comes in a variety of shapes and sizes, including dissolving micro-needles, coated micro-needles, hollow micro-needles, and solid micro-needles.
In 2020, the global micro-needle flu vaccine market is predicted to be worth US$ 1322.1 million, with a CAGR of 6.1 percent during the forecast period (2020-2027).
The micro-needle flu vaccination industry is predicted to develop as government regulatory organizations take steps to reduce the occurrence of influenza flu in the United States.
For example, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention in the United States, which provides advice and guidance on effective disease control in the United States, stated in 2019 that everyone aged 6 months and older should get an influenza flu vaccine every season to reduce the incidence of flu affecting individuals in the United States.
Influence of Coronavirus on the Global Microneedle Flu Vaccine Market (COVID-19)
COVID-19 has spread to over 100 nations worldwide since its outbreak in December 2019, prompting the World Health Organization to designate it as a public health emergency.
According to a report published by the World Health Organization, the coronavirus (COVID-19) had infected more than 45 million people worldwide as of October 30, 2020.
Key Players
Major players operating in the global microneedle flu vaccine market include Sanofi S.A., GC Pharma, Debiotech S.A, 3M Company, NanoPass Technologies Limited, Corium International, Inc, Becton, Dickinson and Company, FluGen, Inc, COSMED Pharmaceuticals Co., Ltd, Microdermics and OraSure Technologies, Inc.
The Microneedle Flu Vaccine Market is made up of micron-sized needles that are organized on a tiny dermal patch.
The primary premise of micro-needles is to rupture the skin layer, resulting in a micron-sized drug delivery channel in which medications can easily be delivered from the epidermis or upper dermis region to the systemic circulation without encountering any barriers.
Microneedle Flu Vaccine Market comes in a variety of shapes and sizes, including dissolving micro-needles, coated micro-needles, hollow micro-needles, and solid micro-needles.
In 2020, the global micro-needle flu vaccine market is predicted to be worth US$ 1322.1 million, with a CAGR of 6.1 percent during the forecast period (2020-2027).
The micro-needle flu vaccination industry is predicted to develop as government regulatory organizations take steps to reduce the occurrence of influenza flu in the United States.
For example, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention in the United States, which provides advice and guidance on effective disease control in the United States, stated in 2019 that everyone aged 6 months and older should get an influenza flu vaccine every season to reduce the incidence of flu affecting individuals in the United States.
Influence of Coronavirus on the Global Microneedle Flu Vaccine Market (COVID-19)
COVID-19 has spread to over 100 nations worldwide since its outbreak in December 2019, prompting the World Health Organization to designate it as a public health emergency.
According to a report published by the World Health Organization, the coronavirus (COVID-19) had infected more than 45 million people worldwide as of October 30, 2020.
Key Players
Major players operating in the global microneedle flu vaccine market include Sanofi S.A., GC Pharma, Debiotech S.A, 3M Company, NanoPass Technologies Limited, Corium International, Inc, Becton, Dickinson and Company, FluGen, Inc, COSMED Pharmaceuticals Co., Ltd, Microdermics and OraSure Technologies, Inc.
0 Comments